| Ytd | -9.73% | |
| 1y | 289.29% |
| Open | 4.31 | Prev Close | 4.33 | Low | 4.29 | High | 4.39 | Mkt Cap | 465.08M |
| Vol | 628.24K | Avg Vol | 1.73M | EPS | -0.91 | P/E | N/A | Forward P/E | -0.19 |
| Beta | 0.41 | Short Ratio | 4.52 | Inst. Own | 46.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 5.53 | 200-d Avg | 5.46 | 1yr Est | 0.87 |
RLMD News
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion o
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicat
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure
Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its s
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.11) per share which beat the ana
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Novo Nordisk A/S (NYSE: NVO - Get Free Rep
ADAR1 Capital Management LLC increased its holdings in Relmada Therapeutics, Inc. (NASDAQ: RLMD) by
CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) was the recipient of a large growth in s
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-s
CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
On Thursday, HC Wainwright initiated coverage on Relmada Therapeutics Inc. (NASDAQ:RLMD) with a prim
HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highli
Analysts changed outlook on top Wall Street names. See all changes on our analyst ratings page. Chec
HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Relmada Therapeutics (N
CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Rel
U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock
US stock futures surge on tech sector news, HPE reports strong earnings, and other tech stocks follo
On May 28, 2026, Relmada Therapeutics, Inc. (the "Company") filed a Certificate of Amendmen
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relm
RELMADA THERAPEUTICS, INC.COMMON STOCKPREFERRED STOCKWARRANTSSUBSCRIPTION RIGHTSDEPOSITARY SHARESPUR
Relmada Therapeutics NASDAQ: RLMD said it remains on track to begin its Phase 3 RESCUE registrationa
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.22) per share which missed the a
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relm
CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relm
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the
Piper Sandler analyst Kelsey Goodwin initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) wit
Mizuho analyst Uy Ear maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and raises t
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.27) per share which missed the a
US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving l
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
Relmada Therapeutics shares rise on promising interim data from Phase 2 trial of NDV-01 for non-musc
HIMS: 54% | Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug De
Pursuant to the terms of the securities purchase agreement, Relmada is selling an aggregate of (i) 2
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Relmada Therapeutics (NASDAQ:
Leerink Partners analyst Andrew Berens upgrades Relmada Therapeutics (NASDAQ:RLMD) from Market Pe
In its written response to Relmada's Type B pre-IND submission, the FDA indicated that a single-
Jefferies analyst Farzin Haque initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Bu